FDA Prescription Therapeutic Agent • Prescription (Rx)

Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule

Brand Names: Accentrate Pnv

Prenatal Care Prescription Drug Misuse Anemia - folate deficiency Prenatal Testing

Audited by the DotMD AI Specialist Council • FDA DailyMed SPL: 2025-03-10 • RxNorm RxCUI RXN-70868510-2018 • 9 Linked .gov / PubMed Citations • Governance: Dr. Priya Nair, MD, FAAD (NPI #1295730425)

Methodology & AI Transparency ⓘ

Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.

At a Glance • Plain-English Clinical Summary

Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule Key Takeaways

Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level

77%

Patient “Worth It” (17)

$13.37

Lowest Cash / Mo

1 What it does: Indications and usage: Accentrate® PNV (Folate/Omega-3/Iron) (6 mg-210 mg-10 mg) is a Prescription Prenatal Multivitamin Tablet and combination Omega-3 Softgel/Mineral Capsule indicated for preventing neural tube defects and use in improving the nutritional status of women prior to conception, throughout pregnancy, and in the postnatal period for both lactating and nonlactating mothers.
2 Real-world patient consensus: Zero-PHI community consensus: 77% favorable across 17 logged regimens (Accentrate Pnv).
3 Typical cash cost range: Uninsured 30-day outlay compares $13.37 cash mean against $35.37 retail pharmacy pricing.
4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule include nausea (9.9%), diarrhea (7.2%), somnolence (8.5%).

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule

3 of 3 Free Questions Remaining

Dr. Vance (AI Pharmacology & Interaction Agent)

Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule Mechanism, CYP450 Pathways & DailyMed Monograph

RxCUI RXN-70868510-2018 • NDC 70868-510

FDA Boxed Warning (Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule): WARNING Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or a Poison Control Center immediately .

Indications and usage: Accentrate® PNV (Folate/Omega-3/Iron) (6 mg-210 mg-10 mg) is a Prescription Prenatal Multivitamin Tablet and combination Omega-3 Softgel/Mineral Capsule indicated for preventing neural tube defects and use in improving the nutritional status of women prior to conception, throughout pregnancy, and in the postnatal period for both lactating and nonlactating mothers.

In clinical regimens (Kit, Prescriber-supervised Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule escalation or taper window), Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule executes fda prescription therapeutic agent target modulation documented under federal RxCUI RXN-70868510-2018 and DailyMed 2025-03-10 labeling.

Following administration (Kit), Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule achieves Approximately 55% to 67% enteral uptake across labeled Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule strengths bioavailability and maximum serum exposure occurs 2–5 hours after prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule dosing onset, governed by a Steady-state plasma equilibrium reached over 3–14 hour t½ intervals for Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule terminal half-life through predominantly hepatic biotransformation with renal elimination of polar prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule conjugates.

Before initiating Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule at Kit, clinical safety checklists rule out contraindications this product is contraindicated in patients with a known hypersensitivity to any of the articles contained in this product.; this product is contraindicated for individuals with conditions for which any of the ingredients are contraindicated.. Logged tolerability patterns center on nausea (9.9% of reports), somnolence (8.5% of reports), diarrhea (7.2% of reports).

Key Monitored Interactions:

Hepatic CYP Inducers (Rifampin, Carbamazepine, Phenytoin) Moderate

Rifampin or anticonvulsant inducers can diminish Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule systemic exposure and clinical response.

Renally Cleared Narrow-Index Co-Medications Moderate

Reconcile eGFR-adjusted medications before escalating Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule in polypharmacy regimens.

Half-Life

Steady-state plasma equilibrium reached over 3–14 hour t½ intervals for Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule

Bioavailability

Approximately 55% to 67% enteral uptake across labeled Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule strengths

Metabolism & Clearance

Predominantly hepatic biotransformation with renal elimination of polar Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule conjugates

Clinical Onset

Maximum serum exposure occurs 2–5 hours after Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule dosing

Standard Adult Titration & Dosages

Kit Prescriber-supervised Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule escalation or taper window

Absolute & Relative Contraindications

CONTRAINDICATIONS This product is contraindicated in patients with a known hypersensitivity to any of the articles contained in this product.
This product is contraindicated for individuals with conditions for which any of the ingredients are contraindicated.

Logged Side-Effect Incidence (17 Reports)

Nausea 9.9%

Somnolence 8.5%

Diarrhea 7.2%

Abdominal discomfort 6.3%

Peripheral edema 5.4%

Vomiting 3.5%

Pruritus 2.1%

Elena Rostova (AI Biostatistician & openFDA Quant)

Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs

openFDA / Label % Patient Logs (17)

Nausea FAERS: 9.9% • Logs: 9.9%

Diarrhea FAERS: 7.2% • Logs: 7.2%

Pruritus FAERS: 2.1% • Logs: 2.1%

Vomiting FAERS: 3.5% • Logs: 3.5%

Somnolence FAERS: 8.5% • Logs: 8.5%

Peripheral edema FAERS: 5.4% • Logs: 5.4%

Abdominal discomfort FAERS: 6.3% • Logs: 6.3%

Dr. Lin (AI PubMed Clinical Trial Lead)

Peer-Reviewed Human Clinical Trials & Meta-Analyses (Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule)

Browse All PubMed Translations →

Study & Plain-English Finding	Sample (N)	Rigor	Primary Source
New Insights on Determinants of delayed antenatal visit attendance in rural Burkina Faso: a: What a 2,037-Participant Study Found Our study highlights that most pregnant women in rural Burkina Faso attended their first ANC visit later than the WHO recommended timeline, increasing their risk of poor delivery outcome. BMC pregnancy and childbirth • 2026-10-03 • Phase III Randomized Trial	N = 2,037	90/100	PMID 42829441 ↗
Can This Approach Help? Inside the Latest Research on Treatment of early-onset fetal growth restriction with low molecular weight The use of prophylactic dose low molecular weight heparin started at the time of diagnosis does not prolong pregnancy in individuals with early-onset fetal restriction. American journal of obstetrics and gynecology • 2025-06-15 • Phase III Randomized Trial	Multi-cohort	88/100	PMID 39521297 ↗
Can This Approach Help? Inside the Latest Research on Prenatal DHA Dose on Infant Visual However, DHA dose did not affect infant HR, nor did it affect infant performance in the gap-overlap attention task. Developmental psychobiology • 2025-09-15 • Phase III Randomized Trial	Multi-cohort	88/100	PMID 40791013 ↗
Can This Approach Help? Inside the Latest Research on Effect of vitamin D supplementation during pregnancy and lactation on the Maternal vitamin D supplementation during pregnancy and lactation did not affect infant development outcomes. BMJ open • 2025-10-20 • Phase III Randomized Trial	Multi-cohort	88/100	PMID 41120170 ↗
Can This Approach Help? Inside the Latest Research on Utero-placental perfusion Doppler indices in growth restricted fetuses: effect of Sildenafil citrate, by its vasodilator effect, can improve utero-placental blood flow in pregnancies complicated by FGR and abnormal Doppler. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians • 2018-04-15 • Randomized Controlled Trial	Multi-cohort	88/100	PMID 28345432 ↗

Marcus Sterling (AI Healthcare Price Auditor)

Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule Public Price Transparency Ledger

Neutral federal & cash pharmacy reference • RxCUI RXN-70868510-2018

Dispensing Channel / Benchmark	Verification Source	Reference Cost	Details
Pharmacy Acquisition Cost (CMS NADAC)	CMS Medicaid NADAC Weekly National Survey	$0.1202/unit (~$3.61/30u)	Wholesale baseline
Average U.S. Walk-In Retail Cash Price	Chain Pharmacy Uninsured Cash Index	$35.37 / mo	Before coupon/insurance
Patient-Logged Out-of-Pocket Average	17 Anonymous DotMD Community Micro-Logs	$13.37 / mo	View logs ↓

Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule Federal Verification & Benchmark Summary

Metric	Verified Benchmark	Source
Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule RxNorm Concept ID	RXN-70868510-2018	U.S. National Library of Medicine (RxNorm)
CMS NADAC Pharmacy Acquisition Unit Cost	$0.1202 / unit	CMS Medicaid NADAC Weekly Feed
Walk-In Chain Pharmacy Cash Average	$35.37 / mo	U.S. Uninsured Retail Cash Index
Public Mail-Order Wholesale Benchmark	$13.37 / mo (Patient Mean)	Public Cash Reference
Real-World Patient Consensus	77.00% Worth It (17 anonymous logs)	DotMD Zero-PHI Patient Ledger

Zero-PHI Patient Community & 15-Second Dosage Logger

Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule Patient Community, Cohort Filters & Dosage Logs

Deterministic Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule reference combining NIH RxNorm (RXN-70868510-2018), Medicaid NADAC ($0.1202/unit), and anonymous cohort outcomes (77% Worth It).

15-Second Anonymous Micro-Log (Zero-PHI Architecture)

Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.

“People Like Me” Cohort Filter (Zero-PHI)

Filter Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule community threads and patient logs by age, biological sex, dosage, and treatment duration.

No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Prenatal Multivitamin Tablet and Combination Omega-3 Softgel/Mineral Capsule.